Are investors over-reacting to the COVID-19 situation?

Concerns about the economic impact of the Coronavirus is weighing heavily on markets. However, we do not yet believe that the virus represents a structural slowdown in growth.

03 Mar 2020
  • The duration more than the severity of the coronavirus that most threatens global growth and risk assets, any slowdown in new cases would therefore likely represent an important milestone
  • US political risk is also weighing on equities
  • Our base case remains that the coronavirus is a transitory not recessionary shock; there is scope for a meaningful rebound in demand and investor confidence
  • We expect rate cuts from the US, Australia, Canada, UK and others in a bid to ease financial conditions and improve sentiment; a coordinated central bank response would be powerful message to markets
  • Moratorium on China tariffs an obvious move for President Trump to boost re-election chances; scope for fiscal stimulus across major economies too

What has been happening in markets?

As the number of reported coronavirus cases outside of China continues to rise, so do broader investor concerns about the potential economic impact of the virus. The prevailing market narrative has shifted swiftly from the coronavirus being a predominantly China issue, to the coronavirus being a global problem that might result in recession.

But the repricing of growth expectations and risk across asset classes due to the coronavirus has been far from uniform. Industrial commodities, most notably oil, and commodity sensitive equities and currencies have been among the hardest hit. Within equity markets, one of the most notable and surprising features of market price reaction in recent weeks has been the material outperformance of on-shore Chinese equities. Traditional safe havens such as government bonds have outperformed significantly amid the flight to safety, with yields sharply lower and at all-time lows across a number of major countries. 

Meanwhile, US high yield bonds in aggregate have fared considerably better than equities in the sell-off despite their sensitivity to a growth slowdown, exposure to consumer spending and usual positive correlation to oil.

To put the scale of last week's market action in an historical context, the weekly fall of over 11% in local currency terms for the MSCI World was the third largest over the past 50 years and the biggest weekly loss since the financial crisis. The VIX Index, Wall Street's so-called 'fear gauge', closed the week at levels not seen since the European debt crisis.

Are investors over-reacting to the COVID-19 situation?

We should acknowledge the high degree of uncertainty that surrounds the potential global economic impact of the coronavirus. That uncertainty is the principal driver of the increase in volatility and the drawdown in risk assets. The transmission mechanisms of the virus to economic demand are nuanced. But in simple terms the potential impact is significant because the virus restricts nearly all parts of the economy via the flow of people and the flow of goods.

As the virus spreads further across Europe, US and elsewhere, the probability that it could ultimately lead to a more significant slowdown in global activity is increasing. Efforts to contain the spread of the virus by closing businesses and imposing quarantine are themselves potentially negative to short-term growth potential.

Significant as the potential impact is, we do not yet believe that the virus represents anything like the structural downward shift in global growth that was the result of the financial crisis, but accept that history does not present many helpful guides when it comes to the current scenario.

In our view, the dislocation between market reaction in US equities versus US High Yield bonds suggests that strong flows have weighed on equities in particular.

Our read through of the relative strength in High Yield is that credit investors do not yet believe that the coronavirus is an event that threatens a more material increase in corporate bond defaults.

Nonetheless, the distribution of potential outcomes for global growth is changing. This mainly reflects the danger that the market sell-off becomes self-fulfilling, with consumer and business behavior materially curtailed by newsflow and by the drawdown in risk assets.

Is it just the coronavirus driving risk assets lower?

In our view, one of the drivers to recent equity market falls was the potentially dangerous circularity of the virus and perceived US political risk. Falling equities and any deterioration in economic conditions are likely to boost the chances of a more progressive Democratic Party candidate such as Bernie Sanders winning the US presidency, for which investors are understandably demanding a higher risk premium.

But the decisive victory of Sanders' principal opponent for the Democratic presidential nomination in the South Carolina primary at the weekend – centrist candidate and former Vice-President Joe Biden – provides at least a temporary circuit breaker to that negative circularity. Should Biden gain further ground ahead of the July Democratic Convention, investors will begin to unwind some of the risk premium that has been priced in for the threat to corporate profits from the Democratic Party. 'Super Tuesday', in which 14 US states hold their primaries, is therefore a key date. For all the talk of the coronavirus, perceptions of US political risks are likely to be a major driver of US risk asset returns in the coming months.

How long and how much could the coronavirus impact global economic growth?

We assume for now that the rate of growth in new coronavirus cases in China will continue to slow. But it is not a given. The flash PMIs for February, the first data points we have for a whole month of the virus impact, show Chinese activity across both manufacturing and services slumping to all-time lows with levels significantly lower even than the financial crisis. We currently estimate that annual demand growth in China will be around 50 basis points (bps) to 75bps lower than pre-virus consensus forecasts of 5.8% with the impact firmly focused in calendar Q1 and Q2.

But we should not forget the secondary economic impact of the coronavirus in China via the disruption to global supply chains. We are likely to hear a lot more about it from global corporates in the coming weeks. According to a recent report (Business Impact of the Coronavirus – Dun & Bradstreet) over five million companies globally – and some 94% of the Fortune 1000 – have one or more suppliers in the area of China affected by the coronavirus. China is returning to work and activity levels are rebounding. But as positive as that is, a significant degree of disruption for global corporates is likely for weeks to come.

Outside of China, lower population densities and generally strong public healthcare systems (excluding the US) are likely to limit both the spread of the virus in developed countries and its subsequent mortality rate. But the disciplined and effective response of the Chinese authorities to-date is also at the upper bound of what might be expected in terms of response from any given country.

At a minimum, the continued rise in cases outside of China lengthens the period during which the virus is likely to impact global growth and remain a source of heightened uncertainty to investors. The increase in uncertainty has clear negative implications for overall short-term demand, for forecast corporate earnings – and for the equity multiple that investors are willing to pay for lower profits growth amid such uncertainty in the short-term.

Based on the progression of the virus in China, our view is that the disruption to growth and risk asset volatility are likely to remain elevated well into Q2 while the number of cases in major economies continues to rise. To-date consensus forecasts have cut only around 20bps off global growth expectations for 2020 to around 2.5%, and around 4% off 2020 global earnings growth forecasts (Source: Refinitiv, Citigroup).

We believe it is the length more than the severity of the coronavirus downturn that matters most.

If the impact of the coronavirus is still being felt into the second half of 2020, both consumers and corporates are likely to change their behavior and the coronavirus ceases to be a short-term earnings story and starts to become a credit story.

If it is only a few weeks into Q2, we believe that companies and consumer behavior will be held in check over the short-term but the underlying momentum is unlikely to fundamentally change. In those circumstances we see the potential for a strong demand rebound in the second half of the year that is likely to accompanied by a more forceful return in investor risk appetite.

In short, our base case remains that the coronavirus represents a meaningful demand and supply shock, but one that is unlikely to have a structural impact on growth potential or the long-term equilibrium interest rate. While the precise timing of any demand rebound is not easy to pinpoint in the context of the coronavirus, we see sufficient supports to believe that growth momentum will return around mid-year. It has the potential to do so strongly.

What can counter the negative newsflow?

  1. A slowing of new cases in major economies - would, we believe, represent an obvious but nonetheless important risk milestone for many investors. Based on the experience in China, we believe the high point in new case growth is probably some weeks away as the virus continues to spread. It is self-evident that the development of a successful (and affordable) vaccine would represent the most effective counter to the uncertainty. But industry commentary suggests that this is unlikely in 2020.
  2. Tariff reduction/reversal - On the face of it, geopolitics remain an additional threat to our base case, most notably in the forthcoming US elections and in the ongoing US/China trade disputes. But it is within the sphere of international trade that we see the greatest probability for a potential upside surprise. President Trump is well aware of the importance of a robust economy and rising stock market to his re-election chances. The lifting of US tariffs on Chinese goods is an obvious lever for the White House to pull in a bid to reverse the negative newsflow of the coronavirus.
  3. Further rate cuts - In response to the growing threat to growth from the coronavirus, we expect central banks to increase the policy stimulus in a potentially coordinated fashion. Statements from the US Federal Reserve on February 28 and the Bank of Japan on March 2 very clearly support this view. We anticipate further cuts to key policy rates globally including in the US, Canada, UK and Australia. The recent fall in nominal bond yields further loosens financial conditions globally.
    We would add that even if the lag between stimulus and its impact on the real economy is likely to be longer than usual in developed countries due to the coronavirus, we believe that monetary policy and its accompanying communication retains its power to support sentiment and activity.
  4. Developed economy fiscal stimulus - We believe monetary policy is also likely to be complemented by an increasing fiscal impulse in a wide range of developed countries including Japan and the UK that can further cushion growth.
  5. Chinese policy stimulus - Cuts across key market lending rates, the deferral of loan payments for impacted businesses, cuts to social security payments, fee waivers, automatic re-lending and utility subsidies are just some of the measures already put in place to help struggling Chinese businesses. The Chinese authorities have the full suite of potential policy measures at their disposal to further combat the domestic growth slowdown if necessary. We expect more to come across all policy channels, but see the Chinese authorities turning increasingly to fiscal stimulus via tax cuts and increased infrastructure spending.

How are our asset allocation portfolios positioned?

With all the industry comment coming into 2020 over the threat to traditional multi-asset portfolios from a structural shift higher in equity/bond correlations, recent days have underlined the critical role that government bonds still have to play in improving the risk-adjusted returns potential of multi asset portfolios.

Within the universe of major global nominal government bonds, our favored market is China. On top of attractive yields on a relative basis, we continue to see Chinese government bonds as a very effective multi-asset diversifier in the context of the coronavirus.

The outlook for global equities remains nuanced in a fast changing and dynamic market environment. Global equities remain attractively valued relative to both government and corporate bonds – and we believe that global growth and earnings will rebound in the second half of the year. But in the short-term, the uncertainty around the economic impact of the coronavirus is inconsistent with high levels of portfolio equity risk.

We are therefore focusing on some attractive relative value trades amidst the dislocation – and awaiting better opportunities for higher conviction views on economic cyclicality and equity directionality given the potential for a sharp bounce back. In our view, these are markets that are likely to reward disciplined risk budgeting and diversification.

For Fixed Income, we have reduced credit risk and positioned strategies to benefit from increased demand of high quality sovereign and corporate bonds. Our focus is on developed and emerging markets where central banks still have the scope to manage downside risk through further policy accommodation. We will likely not add any material direct credit risk back into our strategies until we see some sign of stabilization. However, we will look to take advantage of any material increase in credit spread volatility, where feasible.

Within Global Equity markets we have seen a clear 'flight to safety' with defensive sectors outperforming cyclical stocks and growth outperforming value. We have already seen a number of companies providing warnings on earnings with areas such as autos, leisure and airlines especially impacted. We are using such short term dislocation to increase holdings where shares have fallen below our estimates of long term value, while being mindful of the risk of further disruption.

For Emerging Markets Equities, the short-term economic impact from coronavirus could be significant, largely because of the considerable precautions taken (particularly in China), like travel restrictions and factory closures.

In China, many large companies and state-owned enterprises have resumed work, but smaller companies face more of a struggle. Coal mining, steel and food manufacturing have seen faster pace of work resumption, while less so for travel, tourism and auto-related sectors. Depending on the sector and progression of the Covid-19 situation, it is estimated that the impact of work disruptions could last for one to two quarters.

As for supply chain, even prior to Covid-19, the move to reduce dependence on China had started and Covid-19 provides an additional impetus to diversify. Favored destinations are South-East Asia (esp. Vietnam), India and reshoring, especially back to North America, South Korea or Japan. Restructuring the supply chain is often accompanied by automation, benefitting factory automation companies.

But the outbreak of coronavirus is also accelerating fundamental, long-term changes in consumer behavior within emerging markets. For example, consumers are shifting online for services like after-school tutoring; fragmented industries like real estate and restaurants are consolidating; higher demand for better connectivity is driving investment in IT networks, and healthcare companies are investing in R&D and innovation to deliver new drugs and health services.

Despite the uncertainty caused by coronavirus, we remain confident in these fundamental, long-term changes playing out in emerging markets and our portfolios are focused on quality companies associated with them. That said, we remain cautious and haven't made big moves, but we are holding slightly higher cash reserves should opportunities emerge.

From a UBS Hedge Fund Solutions perspective, fundamental strategies may encounter some near term volatility as hedge funds digest the potential economic headwinds related to containment of the virus, but our relatively low net exposure should help mitigate the risk so we can be front footed after the uncertainties are resolved. Our overweight to macro trading and fixed income relative value should provide the opportunity to monetize the volatility created as markets digest the potential recessionary risk and government policy response to the crisis.

For UBS O'Connor, virus fears and rapid market sell-off have sparked an aggressive bout of de-risking within global equity and credit markets. While diversification and tight beta management has provided defensive characteristics for our strategies, recent flows indicate that hedge funds have entered a more aggressive de-risking phase, which is creating both risk and opportunity for our strategies. We are watching closely for opportunities to add to risk over the coming week, and are focused on those segments of the market where dislocations have been extreme relative to beta performance. We expect markets to begin to normalize over the coming week, as investors increasingly discount the economic impact associated with the virus and a potential policy response becomes apparent to the markets.

Coronavirus is a risk to economies and real estate markets, particularly in Asia Pacific, but we believe that any impact will be short term if it is contained. There has been a dip in investment activity and share of international capital flows. We have seen interest rate cuts leading to yield falls in some markets, with real estate pricing around average versus index linked bonds. We do not see a big inflation risk and our analysis suggests that real estate offers suitable inflation protection.

Subscribe now

Perspectives matter. Tune in to our insights.

More insights

Singapore Retail Investors


This website is not intended for and should not be accessed by persons located or resident in any jurisdiction where (by reason of that person's nationality, domicile, residence or otherwise) the publication or availability of this website is prohibited or contrary to local law or regulation or would subject any UBS entity to any registration or licensing requirements in such jurisdictions. It is your responsibility to be aware of, to obtain all relevant regulatory approvals, licenses, verifications and/or registrations under, and to observe all applicable laws and regulations of any relevant jurisdiction in connection with your entrance to this website. Each investment product and service referred to on this website is intended to be made available only to residents in Singapore.

UBS reserves the right to change, modify, add or remove content on the website as well as these terms at any time for any reason without notice. Such changes shall be effective immediately upon posting. You acknowledge that by accessing our website after we have posted changes to these terms, you are agreeing to these terms as modified.

The materials on this Website are distributed by UBS Asset Management (Singapore) Ltd (company registration number: 199308367C), which is licensed by Monetary Authority of Singapore ("MAS") in Singapore pursuant to the Securities and Futures Act (Chapter 289 of Singapore). UBS Asset Management (Singapore) Ltd is part of the Asset Management business division of UBS Group AG. UBS Asset Management (Singapore) Ltd together with UBS Group AG and its group companies shall collectively be referred to as "UBS".

The information contained in this Website has been prepared and is intended for general circulation. The information does not constitute advice and does not take into account the specific investment objectives, financial situation, or particular needs of any particular person. The investment services or products referred to in this Website may not be suitable for all investors. UBS recommends that you independently evaluate particular investments and strategies and seek independent advice from a financial adviser regarding the suitability of such investment products, taking into account your specific investment objectives, financial situation and particular needs, before making a commitment to purchase any investment products. Investment involves risks. You should be aware that investments may increase or decrease in value and that past performance is not indicative of future performance.

The information contained in this Website is not an offer to buy or sell or the solicitation of an offer to buy or sell any investment product or to participate in any particular trading strategy. UBS, its officers and/or employees may have interests in any of the investment products referred to on this Website by acting in various roles. UBS, its officers and/or employees may receive fees, commissions or other benefits for acting in those capacities. In addition, UBS, its officers and/or employees may buy or sell investment products as principal or agent and may effect transactions which are not consistent with the information set out in this Website.

You fully understand and agree that, by making available this Website, UBS should not be construed as making: (a) any endorsement of any investment product referred to in this Website; (b) any representation that UBS has performed any due diligence on any investment product referred to in this Website; or (c) any representation that the information in this Website is complete, accurate, clear, fair and not misleading. The use or reliance on any such information contained in this Website is at your own risk and any losses which may be suffered as a result of you entering into any investment are for your account and UBS shall not be liable for any losses arising from or incurred by you in connection therewith. UBS is not responsible or liable for the accuracy and completeness of any such information or the performance or outcome of any investment made by you after receipt of such information, irrespective of whether such information was provided at your request.

Using, copying, redistributing or republishing any part of this Website without prior written permission from UBS is prohibited. Any statements made regarding investment performance objectives, risk and/or return targets shall not constitute a representation or warranty that such objectives or expectations will be achieved or risks are fully disclosed. The information and opinions contained in this Website is based upon information obtained from sources believed to be reliable and in good faith but no responsibility is accepted for any misrepresentation, errors or omissions. All such information and opinions are subject to change without notice. A number of comments in this Website are based on current expectations and are considered “forward-looking statements”. Actual future results may prove to be different from expectations and any unforeseen risk or event may arise in the future. The opinions expressed are a reflection of UBS’s judgment at the time this document is compiled and any obligation to update or alter forward-looking statements as a result of new information, future events, or otherwise is disclaimed.

UBS does not hold out any of its officers and/or employees as having any authority to advise you, and UBS does not purport to advise you on any investment product. Any investment will be made at your sole risk and UBS is not and shall not, in any manner, be liable or responsible for the consequences of any investment.

This Website and its contents are provided on an “as is” and “as available” basis. UBS does not warrant: (a) the accuracy, timeliness, adequacy commercial value or completeness of this Website or its contents, and expressly disclaims any liability for errors, delays or omissions in the contents, or for any action taken in reliance on the contents; (b) that your use of and/or access to this Website or its contents, will be uninterrupted, timely, secure or free from errors or that any identified defect will be corrected; (c) that this Website or any content will meet your requirements or are free from any virus or other malicious, destructive or corrupting code, agent, program or macros; (d) that any information, instructions or communications posted or transmitted by you through this Website is secure and cannot be accessed by unauthorised third parties; and (e) that use of the contents in this Website by you will not infringe the rights of any third parties. No warranty of any kind, implied, express or statutory, including but not limited to the warranties of non-infringement of third party rights, title, merchantability, satisfactory quality or fitness for a particular purpose and freedom from computer virus or other malicious, destructive or corrupting code, agent, program or macros, is given in conjunction with this Website.

You hereby agree to indemnify UBS and any of its officers, employees or agents against, and to keep UBS and any of its officers, employees or agents harmless from, any claims (actual and threatened), settlement sums, liability, loss, damages, costs (including solicitor and client costs and expenses (legal or otherwise)), charges, expenses, actions, proceedings, whether foreseeable or not which we may sustain, suffer or incur, directly or indirectly out of or in the course of or in connection with any the following: (a) any use of this Website or the contents by you, or any part thereof; (b) UBS having made available the Website; (c) any breach of these Terms by you, however arising; or (d) any negligence, act or omission, wilful default, unlawful act, fraud and/or misconduct on your part or violation of any rights of another person or entity by you.

The funds referred to in this Website have been authorised or recognised by the MAS for sale to the public in Singapore (the “Funds”). Copies of the registered Singapore prospectuses ("Prospectuses") referred to in this Website have been lodged with and registered by the MAS. The MAS assumes no responsibility for the contents of the Prospectuses. The registration of the Prospectuses by the MAS does not imply that the SFA or any other legal or regulatory requirements have been complied with.

MAS registration is not a recommendation or endorsement of a Fund nor does it guarantee the commercial merits or performance of such Fund. It does not mean that a Fund is suitable for all investors nor is it an endorsement of its suitability for any particular investor or class of investors. UBS Asset Management (Singapore) Ltd has been appointed as the representative for the Funds in Singapore for the purposes of performing administrative and other related functions relating to the offer of Shares under Section 287 of the Securities and Futures Act, Chapter 289 of Singapore (the "SFA") and such other functions as the MAS may prescribe.

You may not assign your rights under the Terms without our prior written consent. UBS Asset Management (Singapore) Ltd may assign our rights under the Terms to any third party.

No person or entity who is not a party to the Terms shall have any right under the Contracts (Rights of Third Parties) Act, Chapter 53B of Singapore or other similar laws to enforce any term of the Terms regardless of whether such person or entity has been identified by name, as a member of a class or as answering a particular description. For the avoidance of doubt, this shall not affect the rights of any permitted assignee or transferee of the Terms.

These Terms shall be governed by, and shall be construed in accordance with, the laws of Singapore. The courts of Singapore shall have exclusive jurisdiction to hear and determine any suit, action or proceeding, and to settle any disputes, which may arise out of or in connection with these Terms and, for such purposes, you agree to submit  to the jurisdiction of the courts of Singapore. Each party hereby waives any objection which it might at any time have to the courts of Singapore being nominated as the forum to hear and determine any proceedings and to settle any disputes and agrees not to claim that the courts of Singapore are not a convenient or appropriate forum.

© UBS 2021 - the key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.